Ursodeoxycholic acid prevents gastrointestinal disorders caused by anticancer drugs.
Gastrointestinal disorders often occur during systemic chemotherapy. In an attempt to prevent these side-effects, ursodeoxycholic acid was administered during the systemic chemotherapy. This compound significantly alleviated the side-effects, as assessed by an increase in appetite, total serum protein level and body weight. However, in patients with a deficiency in pancreatic exocrine secretion and/or obstructive jaundice due to metastasis to common bile duct, the effects were nil.
D000855:Anorexia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001798:Blood Proteins / Q000032:analysis; D001835:Body Weight / Q000187:drug effects; D003840:Deoxycholic Acid / Q000031:analogs & derivatives*; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001798:Blood Proteins; D003840:Deoxycholic Acid; D014580:Ursodeoxycholic Acid